Biogen’s Singhal Offers A Look Into Company's Pipeline Review

Explains How Company Validated Its Assets, Reduced Portfolio Risk

Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.

Biogen logo is seen at its headquarters in Cambridge, Massachusetts
Biogen's 2024 readouts include a Phase III lupus trial • Source: Shutterstock

Biogen, Inc. has been no stranger to the biopharma spotlight during the past few years, but behind the scrutiny of the company’s Alzheimer’s drug approvals and its need to return to revenue growth, head of development Priya Singhal spearheaded a thoughtful approach to restructuring the pipeline that began before Christopher Viehbacher became CEO and instituted commercial and R&D cost-cutting aimed at resetting Biogen’s trajectory.

Key Takeaways
  • Biogen is still building towards a return to revenue growth and head of development Priya Singhal has been one of the architects of the path forward.

More from Business

More from Scrip